




Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first and only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and direct quantification of total blood, plasma & red cell composition compared to patient-specific norms. Over 65,000+ tests performed in leading hospitals across the U.S., enhancing hospital performance outcomes in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all.

STOCK SYMBOL	DXR (NASDAQ)
Stock Price	\$9.58 (a/o 09/08/23)
Market Cap	\$45.9M (a/o 09//23)
52-Wk Range	\$7.81 - \$14.55
Shares Outstanding	4.8M
Free Float	2.0M
Insider Ownership	57.4%

IMPROVED OUTCOMES

Significantly Reduce Heart Failure Mortality & Readmissions*

Propensity matched-control trial in community hospital | n = 245, Mixed HFpEF/HFrEF



Blood Volume Measurements Improved ICU Survival†

Prospective randomized control trial in surgical ICU | n = 100, 70% Septic Shock/Sepsis/40% ARDS



*Strobeck JE, et al., JACC-HF, 2018;11:940-948 †M. Yu, K. Pei, S. Moran, et al. A prospective randomized trial using blood volume analysis in addition to pulmonary artery catheter compared with pulmonary artery catheter alone to guide shock resuscitation in critically ill surgical patients. Shock, 35 (2011), pp. 220-228.

BVA On Admission Results in 2.6 Days Reduction in Length of Stay



Analysis of 71 Hospitalized Heart Failure Patients. Strobeck JE, et al., JACC-HF, 2018;11:940-948. Presented at HFSA ASM 2022.

End the Debate

"Blood volume analysis offers providers a unique opportunity to reduce heart failure readmissions and mortality in both the HFpEF and HFrEF populations. We have used the technology at our center extensively and have found it to be hugely informative and cost-effective."

John Inffertes
MD, MPH, FACC, FAHA, FAAP, HFSA, FRCPE

HIGHLIGHTS

- ✓ 59.5% increase YOY in diagnostic kit sales
- ✓ Clean capital structure, strong balance sheet, no warrants, small float
- ✓ Deep & growing IP portfolio with patented technology
- ✓ FDA-cleared, ISO 13485 certified, actionable results within 1-hour
- ✓ "Gold Standard" methodology with 98% accuracy
- ✓ Enables optimal patient outcomes shown to be highly cost effective, reduces mortality and length of stay
- ✓ Reimbursed with CPT & APC codes outpatient & inpatient settings
- ✓ Over \$12B in total addressable global market
- ✓ Razor/Razorblade Model – capital equipment/recurring diagnostic
- ✓ Over 65,000+ tests performed to evaluate blood volume
- ✓ Broad applicability across a growing array of medical conditions
- ✓ Developing a rapid, rugged, portable blood volume analyzer slated for FDA submission in 12 months for both military & civilian use as well as a novel patent-pending fluorescent tracer
- ✓ Over 140+ published peer reviewed studies, abstracts, presentations & trials
- ✓ Several ongoing multicenter trials underway to expand utilization
- ✓ Fully owned, 20,000 SF DORO production/research facility with level 4 clean rooms

SALES MODEL

BVA-100 Device Price

Acquisition: \$85,000

Lease: \$2,750
Per Month

Volumex™ Single Use Kit Price

\$385 + S&H

Daxor ezBVA Lab Service

\$965

Razor/Razorblade Model

- Sale & lease of BVA-100 diagnostic systems
- Recurring sales of single use test kits
- Multi-million-dollar contract awards & grants

SALES & DISTRIBUTION CHANNELS

Leading Third Party Distributors

L1 Enterprises – provider of medical equipment & supplies to the government marketplace

Concordance Healthcare Solutions

Direct Sales Force

Major Medical Centers, Hospitals, Clinics, Government, & DoD

International Expansion Through Distributors With ISO 13485 Certification

CONTRACT & GRANT AWARDS

Over \$3.2 Contract Awards From DoD For Next-Generation Portable BVA System and Development of Fluorescent Tracer

Developing a rapid, rugged, portable blood volume analyzer slated for FDA submission in 12 months for both military & civilian use as well as a novel patent-pending fluorescent tracer.

Partnership with NIH/(CAPCaT) Driving Point of Care Product Innovation & Market Growth

Grant to develop a smart, point-of-care heart failure diagnostic for quantification of intravascular fluid overload to enable precision diuretic dosing.

GROWTH CATALYSTS & VALUE DRIVERS

Extensive R&D drives unique and expanding technology patent portfolio & product development.

Increasing partnership programs with leading clinical and commercial alliances.

Additional clinical outcomes supplementing the clinical & economic benefits of BVA.

Launch of next-generation technology promising a leap in the speed & ease of use to broaden the market for our tests.

EXCELLENT VALUE IN HEALTHCARE WITH REIMBURSEMENT

Blood Volume-Guided Treatment Extremely Cost-Effective[†]

Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF

2.32 QALY

Average Life-Extension
Per Patient

Well above 0.227 previously reported[‡]

5X More

Cost-Effective

Than far below the threshold of \$50,000

Medicare



Private Insurance



Inpatient



Outpatient



Codes:
CPT & APC

[†] Strobeck JE, Feldschuh J, Williams BA, et al. Cost-Effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure. Presented at HFSA 2020 Virtual Conference.

[‡] Rankin, et al. Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses. Heart Failure Reviews (2019), 24:549-563.

Over 65,000+ Tests Performed to Evaluate Blood Volume



Daxor Corporation

107 Meco Lane, Oak Ridge, TN 37830

865-425-0555 | info@daxor.com | daxor.com

Forward Looking Statement: Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation does not constitute an offer to sell or a solicitation of an offer to buy any security.